Core Insights - DuPont de Nemours, Inc. (DD) has launched AmberChrom TQ1 chromatography resin aimed at purifying oligonucleotides and peptides for biopharma applications, enhancing its product portfolio and establishing a new benchmark in the industry [1][2][3] Group 1: Product Launch and Features - The AmberChrom TQ1 chromatography resin is an agarose-based product that offers higher loading capacity, increased throughput, and lower pressure requirements compared to competing products, making it suitable for high-resolution separations and large-scale purifications [2] - The resin is designed to work in conjunction with existing AmberChrom XT and CG chromatography resins, facilitating the purification of various oligonucleotide feeds and aiding in the crude purification of peptide feeds [3] Group 2: Performance Validation - DuPont has published internal application studies using real-world drug feeds to validate the performance characteristics of the AmberChrom TQ1 resin, supporting its integration into processes from drug discovery to commercialization [3] Group 3: Financial Outlook - For the second quarter, DuPont projects net sales of approximately $3.2 billion, operating EBITDA of around $815 million, and adjusted earnings per share of about $1.05, reflecting a seasonal increase in sales [6] - The company has maintained its full-year 2025 guidance, indicating confidence in its financial performance moving forward [6] Group 4: Stock Performance - DuPont's stock has experienced a decline of 14.5% over the past year, which is less severe compared to the industry's overall decline of 26.6% [5]